Lilly Xigris Label Could Exclude Lower-Risk And Sickest Sepsis Patients
Executive Summary
Xigris, if approved, should be restricted to those severe sepsis patients defined by exclusion criteria in Lilly's pivotal trial, FDA's Anti-Infective Drug Advisory Committee recommended Oct. 16.
You may also be interested in...
Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Data requirements for generic biologics approved under the 505(b)(2) process will be taken up by FDA over the next six months, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said
Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate
Data requirements for generic biologics approved under the 505(b)(2) process will be taken up by FDA over the next six months, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said
Lilly Xigris Sepsis Benefit Defended By FDA In NEJM
An FDA analysis of Xigris PROWESS trial data suggests that Lilly's tightening of patient exclusion criteria during the study does not account for greater drug benefit seen after the protocol change